European Commission Approves Merck’s Anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab), for Both First-line and Previously-treated Patients with Advanced Melanoma
Dateline City:
KENILWORTH, N.J.
KEYTRUDA Demonstrated Superior Survival versus Ipilimumab in a Phase 3 Clinical Trial
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the European Commission has approved KEYTRUDA®
(pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of
advanced (unresectable or metastatic) melanoma in adults. The European
Commission approval of KEYTRUDA i...
Source: Merck.com - Corporate News - July 22, 2015 Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news
Merck Marks 30-Year Milestone in Commitment to Innovation and Care in HIV/AIDS
Dateline City:
KENILWORTH, N.J.
Unveils “Positively Committed” Campaign at International AIDS Society Conference
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that the company's commitment to HIV and AIDS, which
started with a research and development program initiated in the
mid-1980s during the early years of the epidemic, is now entering its
fourth decade.
Language:
...
Source: Merck.com - Corporate News - July 21, 2015 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck to Hold Second-Quarter 2015 Sales and Earnings Conference Call on July 28
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
will hold its second-quarter 2015 sales and earnings conference call
with institutional investors and analysts at 8:00 a.m. EDT on Tuesday,
July 28. During the call, company executives will provide an overview of
Merck’s performance for the quarter.
Language:
English
Contact:
...
Source: Merck.com - Corporate News - June 26, 2015 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News Source Type: news
Merck Manual and MSD Manual Launch Global Medical Knowledge 2020 to Provide Free Access to Credible Medical Information on Every Continent by 2020
Multimedia
Dateline City:
KENILWORTH, N.J.
Survey: Americans point to overwhelming amount of online medical information,
inability to judge quality of online sources as biggest barriers to increasing medical knowledge
KENILWORTH, N.J. – Merck Manuals (called MSD Manuals outside of the United States and Canada), one of the world’s most widely-used medical resources since 1899, today announced the launch of Global Medical Knowledge 2020 – a...
Source: Merck.com - Corporate News - June 17, 2015 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck Launches New Program That Encourages Women to “Rule the Real Talk” and Prioritize Their Sexual Health
Discussions about Birth Control Options
KENILWORTH, N.J.-– Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the results of a recent on-line survey about women’s views on relationships and sex, which found that women are less assertive about initiating discussions about their sexual health than they are about other important areas of their lives. That’s why Merck is launching an educational campaign called “Rule the Real Talk” with Dr. Logan Levkoff, relationship and sex expert, and Dr.
Language:
English
...
Source: Merck.com - Corporate News - June 11, 2015 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Amgen and Merck Announce Expansion of Collaboration to Support Studies of Talimogene Laherparepvec in Combination with KEYTRUDA® (pembrolizumab) in Patients with Head and Neck Cancer
Dateline City:
THOUSAND OAKS, Calif. and KENILWORTH, N.J.
Companies Also Plan to Initiate Phase 3 Trial in Combination for Advanced Melanoma
THOUSAND OAKS, Calif. and KENILWORTH, N.J., - May 29, 2015 – Amgen (NASDAQ: AMGN) and Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, today announced an expanded collaboration to evaluate the efficacy and safety of talimogene laherparepvec, Amgen’s investigational oncolytic immunotherapy, in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-...
Source: Merck.com - Corporate News - May 29, 2015 Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news
Merck Announces Third-Quarter 2015 Dividend
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that the Board of Directors has declared a quarterly
dividend of $0.45 per share of the company’s common stock for the third
quarter of 2015. Payment will be made on July 8, 2015, to stockholders
of record at the close of business on June 15, 2015.
About Merck
Language:
English
Contact:
...
Source: Merck.com - Corporate News - May 26, 2015 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News Source Type: news
Merck Receives Positive CHMP Opinion for KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Melanoma
Dateline City:
KENILWORTH, N.J.
Opinion for KEYTRUDA Based on Efficacy and Safety Data in More than 1,500 Patients with Advanced Melanoma as Both First-Line Therapy and in those Previously Treated
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the Committee for Medicinal Products for Human Use
(CHMP) of the European Medicines Agency (EMA) has adopted a positive
opinion recommending appro...
Source: Merck.com - Corporate News - May 22, 2015 Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news
Merck to Present at the UBS Global Healthcare Conference
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that Adam Schechter, executive vice president and
president, Global Human Health, Merck, is scheduled to present at the
UBS 2015 Global Healthcare Conference in New York on May 19, 2015 at
10:30 a.m. EDT. Investors, analysts, members of the media and the
general public are invited to listen to a live audio webcast of the
presentation at http://www.merck.com/investors/webcasts-...
Source: Merck.com - Corporate News - May 18, 2015 Category: Pharmaceuticals Tags: Corporate News Source Type: news
2015 ASCO Annual Meeting: New Data in 10 Different Cancers from Merck’s Rapidly Expanding Immuno-Oncology Research Program for KEYTRUDA® (pembrolizumab) to be Presented
Dateline City:
KENILWORTH, N.J.
New Findings Show Anti-tumor Activity of KEYTRUDA in Five Additional Cancers: Colorectal, Esophageal, Ovarian, Renal Cell Carcinoma and Small-Cell Lung Cancer
First-Time Presentations of DNA Mismatch Repair Deficiency Data in Colorectal and other Cancers and Nanostring RNA Data in Melanoma, Head and Neck and Gastric Cancers
Industry-leading Number of PD-1 Clinical Trials Resulting in Growing Body of Data for KEYTRUDA across 13 Tumor...
Source: Merck.com - Corporate News - May 13, 2015 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News Source Type: news
Merck Announces First-Quarter 2015 Financial Results
Dateline City:
KENILWORTH, N.J.
First-Quarter 2015 Non-GAAP EPS of $0.85, Excluding Certain Items; GAAP EPS of $0.33
Company Narrows and Raises 2015 Full-Year Non-GAAP EPS Target to $3.35 to $3.48, Excluding Certain Items; Lowers 2015 Full-Year GAAP EPS Target to $1.58 to $1.85
First-Quarter 2015 Worldwide Sales Were $9.4 Billion, a Decrease of 8 Percent, Reflecting Net Unfavorable Impact of Acquisitions and Divestitures and a 5 Percent Negati...
Source: Merck.com - Corporate News - April 28, 2015 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News Source Type: news
Merck Announces Publication of Pivotal Data from Phase 3 Clinical Studies of ZERBAXA™ (Ceftolozane/Tazobactam) in The Lancet and Clinical Infectious Diseases
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that The Lancet and Clinical Infectious
Diseases have published online the results from the pivotal Phase 3
clinical studies of ZERBAXA™ (ceftolozane/tazobactam) for Injection (1
g/0.5 g) in complicated urinary tract infections (cUTI) and complicated
intra-abdominal infections (cIAI), respectively. The results will also
appear in forthcoming print issues of the journals.
...
Source: Merck.com - Corporate News - April 27, 2015 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck Announces Presentation of Phase 2 Clinical Trial Results of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir at the International Liver CongressTM 2015
Dateline City:
VIENNA
Results of C-SALVAGE Study Showed High Sustained Virologic Response Rates in Patients Who Failed Prior Combination Therapy with Certain Direct Acting Antiviral (DAA) Agents
Results of C-SWIFT Study Provide Proof-of-Concept for Shorter Than Twelve Weeks Duration of Treatment with Triple-DAA Regimen in Patients with Chronic Hepatitis C Virus (HCV) Genotypes 1 and 3 Infection
VIENNA – April 25, 2015 – Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced th...
Source: Merck.com - Corporate News - April 25, 2015 Category: Pharmaceuticals Tags: Hepatitis C Newsroom Corporate News Latest News Source Type: news
Tim McGraw, Merck and the American Diabetes Association Challenge Americans with Type 2 Diabetes to Get to Their A1C Goal
Dateline City:
Kenilworth, NJ
Platinum-Recording Artist and Actor Rallies People to Make a Pledge with America’s Diabetes Challenge: Get to Your Goals Program
KENILWORTH, N.J., April 22, 2015 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the American Diabetes Association, today announced that award-winning artist Tim McGraw, who has loved ones impacted by type 2 diabetes, will travel the country to urge people with the disease to get their blood glucose under control.
La...
Source: Merck.com - Corporate News - April 22, 2015 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck Reaffirms Continued Commitment to Developing Innovative Medicines for the Treatment of Infectious Diseases at 25th Annual ECCMID Congress
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today reaffirmed its longstanding commitment to discovering and
developing novel medicines in the global fight against infectious
diseases, including infections caused by resistant bacteria and other
pathogens.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-35...
Source: Merck.com - Corporate News - April 21, 2015 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
